Profile
ACOR ZTS HLN TAK TEVA VTRS
Company Name Acorda Therapeutics, Inc. Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $821.03K $74.68B $43.64B $41.66B $25.66B $14.99B
Employees 0.10K 14.10K 25.41K 49.28K 37.00K 32.00K
CEO Dr. Ron Cohen M.D. Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
ACOR ZTS HLN TAK TEVA VTRS
Quant Rating Score 3 3 3 3 1 3
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Neutral
Trading
ACOR ZTS HLN TAK TEVA VTRS
Last Close $0.661 $165.52 $9.74 $13.14 $22.62 $12.56
High 52 $17.5 $199.94 $10.69 $15.08 $22.62 $13.53
Low 52 $0.66 $145.54 $8.01 $12.6 $10.44 $10.05
Price vs. 52 Week High -96.22 % -17.22 % -8.89 % -12.86 % 0 % -7.17 %
Price vs. 52 Week Low 0.15 % 13.73 % 21.6 % 4.29 % 116.67 % 24.98 %
Total Return
ACOR ZTS HLN TAK TEVA VTRS
1 Month Return 0 % -6.35 % 0.21 % -3.17 % 36.51 % -4.99 %
3 Month Return 0 % -15.04 % -8.72 % -9.63 % 29.55 % 8.74 %
6 Month Return 0 % -6.2 % 15.54 % 1.78 % 39.11 % 19.85 %
9 Month Return -94.45 % -1.77 % 14.19 % -7.4 % 56.76 % 6.17 %
YTD Return -95.62 % -16.14 % 18.35 % -7.92 % 116.67 % 15.97 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACOR ZTS HLN TAK TEVA VTRS
Dividend Yield Percentage (TTM) - 1.04 % 1.64 % 4.58 % - 3.82 %
Dividend Paid and Capex Coverage Ration (TTM) -102.84 % 2.1 % - 1.34 % 3.8 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 0.06 % 192 % - 0.48 %
Payout Ratio (TTM) - 31.44 % - 101.62 % - -65.15 %
Growth
ACOR ZTS HLN TAK TEVA VTRS
Asset Growth -70.24 % -4.28 % -2.18 % 8.25 % -1.2 % -4.67 %
Gross Profit Growth -18.87 % 3.7 % 5.84 % 1.76 % 9.65 % -0.9 %
Revenue Growth -0.79 % 5.74 % 4.09 % 5.87 % 6.17 % -5.14 %
Revenue 3 Year -74.97 % 31.98 % 13.9 % 31.78 % -6.91 % -35.32 %
Revenue 5 Year -92.13 % 53.64 % 32.87 % 147.38 % -23.33 % -41.73 %
Revenue 10 Year -90.22 % 103.1 % 32.87 % 151.81 % -40.82 % -26.57 %
EBIT Growth 44.66 % 6.27 % 9.37 % -56.36 % -84.52 % -52.55 %
Net Income Growth -283.6 % 10.88 % -1.04 % -54.56 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 17.38 % 47.55 % -8.67 % -62.13 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share -336.79 % 71.94 % 59.66 % 60.64 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share -530.12 % 404.24 % 59.66 % 34.95 % -133.42 % -97.12 %
Operating Income Growth 44.66 % 6.27 % 9.37 % -56.36 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 33.17 % 23.06 % 1.79 % -26.69 % -13.96 % -5.18 %
Operating 3 Year CFG 92.54 % 14.12 % 48.8 % -29.96 % 10.09 % 13.84 %
Operating 5 Year CFG -102.93 % 37.69 % 166.36 % 165.35 % -48.98 % -48.37 %
Operating 10 Year CFG -109.96 % 274.61 % 166.36 % 382.49 % -67.94 % -16.8 %
EPS Growth -204.32 % 12.64 % - -55.38 % 76.42 % -97.33 %
EPS Diluted Growth -204.32 % 12.92 % - -54.86 % 76.42 % -97.35 %
Book Value Per Share -233.85 % 15.25 % 1.35 % 12.4 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share -121.6 % 36.7 % -36.6 % 38.97 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share -108.14 % 139.55 % -39.41 % 71.52 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share -110.03 % 476.36 % -39.41 % 194.11 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % -85.58 % 0.92 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -83.69 % 0.17 % - -
Dividend 5 Year Growth Per Share -100 % 198.29 % -66.42 % 144.45 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 101.87 % -100 % -
Debt Growth 10.4 % -16.5 % -9.43 % 24.67 % -6.53 % -4.64 %
Free Cash Flow Growth 32.35 % 22.25 % 1.67 % -31.4 % -19.19 % -7.35 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
ACOR ZTS HLN TAK TEVA VTRS
Gross Profit Margin TTM 79.73 % 68.87 % 60.68 % 55.23 % 49.84 % 40.26 %
Return on Assets TTM -322.92 % 16.93 % 3.26 % 1.99 % -2.38 % -1.97 %
Return on Equity TTM 485.8 % 47.99 % 6.54 % 4.04 % -14.6 % -4.43 %
Return on Capital Employed TTM 17.07 % 26.36 % 7.22 % 4.18 % 1.6 % -0.71 %
Net Income Per EBT TTM 86.53 % 79.65 % 65.38 % 108.74 % 176.38 % 92.81 %
EBT Per Ebit TTM 1252.94 % 91.46 % 82.95 % 52.35 % -125.67 % 359.67 %
EBIT Per Revenue TTM -21.01 % 36.45 % 17.82 % 11.21 % 2.67 % -1.76 %
Cash Flow To Debt Ratio TTM -13.86 % 44.8 % - 16.58 % 9.78 % 13.05 %
Receivables Turnover TTM 12.59 6.49 5.27 6.3 4.84 3.81
Payables Turnover TTM 2.36 7.05 1.23 4.92 3.55 7.23
Inventory Turnover TTM 1.66 1.18 3.03 1.69 2.12 2.2
Fixed Asset Turnover TTM 1982.58 % 259.93 % 604.62 % 240.84 % 277.85 % 561.67 %
Asset Turnover TTM 141.79 % 63.75 % 33.71 % 31.2 % 40.16 % 33.6 %
Operating Cash Flow Per Share TTM -21.86 6.5 - 528.88 1.64 1.93
Free Cash Flow Per Share TTM -22.07 5.1 - 321.24 1.21 1.6
Cash Per Share TTM 753.95 % 378.45 % 5.72 % 57241.03 % 292.94 % 171.57 %
Operating Cash Flow Sales Ratio TTM -23.47 % 32.18 % - 18.42 % 11.07 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.97 % 78.37 % - 60.74 % 73.71 % 83.19 %
Cash Flow Coverage Ratios TTM -13.86 % 44.8 % - 16.58 % 9.78 % 13.05 %
Price To Free Cash Flows Ratio TTM -0.03 32.36 - 13.05 18.55 7.84
Price To Operating Cash Flows Ratio TTM -0.03 25.45 - 7.92 13.66 6.52
Price Cash Flow Ratio TTM -0.03 25.45 - 7.92 13.66 6.52
Income Statement (TTM)
ACOR ZTS HLN TAK TEVA VTRS
Revenue $0.12B $8.54B $11.3B $4263.76B $15.85B $15.43B
Gross Profit $0.07B $5.83B $6.96B $2832.26B $7.65B $6.44B
Gross Profit Ratio 60.86% 68.28% 61.59% 66.43% 48.25% 41.74%
EBITDA $0.01B $3.69B $2.35B $874.6B $1.57B $3.46B
Net Income $-0.25B $2.34B $1.05B $144.07B $-0.56B $0.05B
EPS Diluted -203.59 5.07 0.11 91.16 -0.5 0.05
Balance Sheet (MRQ)
ACOR ZTS HLN TAK TEVA VTRS
Long Term Debt $0B $6.75B $8.8B $5029.93B $18.48B $16.35B
Total Liabilities $0.28B $9.3B $17.33B $7834.79B $35.35B $27.22B
Total Equity $-0.16B $4.99B $16.73B $7274.01B $8.13B $20.47B
Total Investments $0B $0.02B $0.07B $445.7B $0.01B $1.33B
Total Debt $0.19B $6.76B $9.46B $4843.75B $20.15B $18.37B
Total Assets $0.12B $14.29B $34.06B $15108.79B $43.48B $47.69B
Cash Flow Statement (TTM)
ACOR ZTS HLN TAK TEVA VTRS
Net Income $-0.25B $2.34B $1.11B $144.07B $-0.62B $0.05B
Inventory $-0B $-0.36B $-0.13B $-115.74B $0B $-0.61B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $-0.58B
Operating Cash Flow $-0.01B $2.35B $2.1B $716.34B $1.37B $2.8B
Capital Expenditure $-0B $-0.73B $-0.34B $-480.73B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.21
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.51
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.57
ALVOW Alvotech 3.27
AMPH Amphastar Pharmaceuticals, Inc. 37.5144
AMRX Amneal Pharmaceuticals, Inc. 7.765
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 54.72
AQST Aquestive Therapeutics, Inc. 3.495
ASRT Assertio Holdings, Inc. 0.8716
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 10.37
AYTU Aytu BioPharma, Inc. 1.51
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ACOR
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 292.58
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 129.86
VXF Vanguard Extended Market Index Fund 0 190.949
VSTCX Vanguard Strategic Small-Cap Equity Fund Investor Shares 0 40.32
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
VTSAX Vanguard Total Stock Market Index Fund 0 144.71
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 147.65
VITSX Vanguard Total Stock Market Index Fund 0 144.73
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 147.66
VEMPX Vanguard Extended Market Index InstlPlus 0 364.38
VSMPX Vanguard Total Stock Mkt Idx Instl Pls 0 271.49
Unlock